COVID-19

51. Decisions In A COVID-19 World: Combat Stress With Quality Risk Management 4/22/2020

    Few of us have ever lived with so much uncertainty and lack of knowledge as we are facing now. This article explains why a structured approach for making risk-based decisions is so important, particularly when we find ourselves in stressful conditions with conflicting needs on many fronts.

     

52. What To Expect From The FDA During (And After) COVID-19 4/20/2020

    More than 100 non-COVID-19 trials have been put on hold, and only 14 percent of sites are open for enrollment. This dynamic forces an evaluation of the regulatory impacts our industry faces in the wake of COVID-19 and what to expect in the months ahead.

53. “Political” Supply-Chain Decisions In Time Of Crisis 4/16/2020

    At this time of difficult political, economic, and health-related decision-making, the entire nation needs your practiced mix of data centrality, and your experience in partnerships and (supply-chain) systems where qualitative analysis also play a major role.

54. How To Measure COVID-19's Impact On Clinical Trials In A Given Country 4/14/2020

    No one knows how the pandemic will unravel and when (if) things will go back to normal. One thing is clear: At least in the next year, research and patient recruitment strategies for current and new clinical trials will depend on the COVID-19 impact on countries and their landscapes. How can we best evaluate what that impact will be?

55. Clinical Study Risk Management During The COVID-19 Pandemic 4/6/2020

    While COVID-19 has proven to be an extremely trying obstacle for the life science community, it is crucial for organizations to not only focus on the short-term impacts of COVID-19 but on developing a long-term plan of action for how we return to business once the pandemic subsides.

56. Clinical Study Conduct During The COVID-19 Pandemic — Challenges & Solutions 4/6/2020

    Life science companies across the world are scrambling to mitigate the impacts of COVID-19 on their clinical studies and business operations, and there are no clear-cut answers at this time, nor a one-size-fits-all solution. But what we do know is that we are all in this together and that this is another challenge that the biotech industry was built for.

57. Stand By To Stand By: Organizational Contingency Planning 4/6/2020

    The coronavirus (COVID-19) pandemic has been a wakeup call, exposing the vulnerability of the global supply chain and the lack of emphasis placed on contingency planning.

     

58. COVID-19, Medical Drones, & The Last Mile Of The Pharma Supply Chain 4/6/2020

    During crises like this pandemic, bottlenecks in drug distribution and sample testing can be improved through automation, artificial intelligence, and robotics. This article provides an overview of the medical drone industry, with a particular emphasis on its adoption by the pharmaceutical sector to solve logistical problems in healthcare during times of heightened need. 

59. Sign The “50 By 25” Declaration Of Drug Independence 4/2/2020

    Will you become a founding signatory to the aggressive but realistic, "U.S. '50 By 25' Declaration Of Drug Independence"? And dedicate yourself to the goal of reducing dependency on foreign sources for drug materials, intermediates, substances?

60. When Employees Become The Supply Chain: Leadership In A Pandemic 3/30/2020

    With your newly dispersed workforce, employees have in effect become a part of your external supply chain. How can leaders help them get through this time of uncertainty, and continue to perform at a high level? Here's some advice.